Are you Dr. Windsor?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 78 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
880 Montclair Rd
Suite 675
Birmingham, AL 35213Phone+1 205-592-5077Fax+1 205-599-4738
Summary
- Dr. Kevin Windsor, MD is an oncologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama and South Carolina. He is affiliated with Cooper Green Hospital, Princeton Baptist Medical Center, and Grandview Medical Center.
Education & Training
- Medical University of South CarolinaFellowship, Hematology and Medical Oncology, 1986 - 1988
- Medical University of South CarolinaResidency, Internal Medicine, 1983 - 1986
- University of Alabama School of MedicineClass of 1983
Certifications & Licensure
- SC State Medical License 1984 - 2025
- AL State Medical License 1988 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors Start of enrollment: 2013 Mar 29
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Publications & Presentations
PubMed
- 15 citationsSafety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.Johanna C. Bendell, Sunil Sharma, Manish R. Patel, Kevin S Windsor, Zev A. Wainberg
The Oncologist. 2020-11-01 - 66 citationsAndecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I StudyManish A. Shah, Alexander Starodub, Sunil Sharma, Jordan Berlin, Manish R. Patel
Clinical Cancer Research. 2018-08-15 - 22 citationsPhase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphomaShaker R. Dakhil, Robert C. Hermann, Marshall T. Schreeder, Stephanie A. Gregory, Marc Monte
Leukemia & Lymphoma. 2014-01-29